



## **ESPERITE delays publication of 2016 Annual Report**

**Zutphen, The Netherlands – 26 April 2017**

Esperite N.V. (Euronext: ESP, the “**Company**” or “**Esperite**”) announces that additional time is needed for the Company to publish its Annual Report for the fiscal year ended 31 December 2016. Following the unanimous approval by the Company's extraordinary general meeting of shareholders on 21 April 2017 for the subsequent tranches of convertible notes and warrants under the recently announced external financing, the Company's board of directors has decided to update certain parameters related to the Company's budget for the fiscal years 2018 to 2021 that are relevant to the ongoing audit process in connection with going concern and measurement of assets. As a consequence, additional time is needed for the Company's auditor, Ernst & Young Accountants LLP, to complete its audit procedures and audit of the Company's Annual Report. Esperite expects to publish its Annual Report and provide its Q1 2017 Trading Update on or before 19 May 2017.

About ESPERITE N.V.

ESPERITE Group, listed at Euronext Amsterdam and Paris, is a leading international company in regenerative and precision medicine founded in 2000.